06 Jun 2021 / 07:14 H. KUALA LUMPUR: The Ministry of Health (MOH) and the Institute for Clinical Research (ICR) have started clinical trials to study the use and efficacy of Ivermectin for high-risk Covid-19 patients at 12 MOH’s hospitals. Health director-general Tan Sri Dr Noor Hisham Abdullah (pix) said Ivermectin is a Food and Drug Administration (FDA) approved antiparasitic drug widely used for treating several neglected tropical diseases, including onchocerciasis, strongyloidiasis and helminthiases, however, the evidence is inconclusive to recommend routine use of Ivermectin for Covid-19 patients. “The ‘off-label’ use of Ivermectin gained global attention due to some promising results by case studies and clinical trials.